Michel is a co-founder of iTeos and has served as Chief Executive Officer since the Company’s incorporation in 2011. Prior to iTeos, Michel gained 15 years of biotech expertise in target discovery, business development, managerial and commercial responsibilities at Euroscreen before joining Ludwig Cancer Research and founding iTeos.
Michel holds a Bioengineering degree and a Ph.D. in Biochemistry from Université Catholique de Louvain (UCL) and a business certificate from Solvay Business School.
He has authored 51 peer-reviewed publications and is an inventor of 27 patents.
Matthew Call joined iTeos Therapeutics in 2019 as Chief Operating Officer. He has nearly 20 years’ experience in business development and corporate strategy leadership roles in the biotech space. Prior to joining iTeos, Matt served as Chief Operating Officer at Endocyte, a Novartis company, leading all business functions. He led all strategic partnering and licensing activities resulting in numerous successful transactions, including Endocyte’s transformational in-license of PSMA-617, which led to the $2.1 billion acquisition of Endocyte by Novartis. Matt managed Endocyte’s billion-dollar out-licensing partnership with Merck and sat on the Joint Development and Joint Commercialization Committees. During his tenure at Endocyte, Matt also supervised new product planning, strategic planning, project management and marketing. Matt started his career in corporate strategy, business development and alliance management in the high tech space.
He has a BA from Brigham Young University and an MBA from Purdue University.
Scott joined iTeos as Chief Scientific Officer in July 2018. Prior to this, he was the Chief Technology Officer at Surface Oncology. At Surface, Scott oversaw all antibody generation, engineering, production and protein characterization. He also managed all preclinical IND enabling studies and GMP manufacturing of antibodies. Scott is an accomplished scientist who directed research that has led to the development of several FDA-approved and marketed biological products.
Scott joined Surface from Arteaus Therapeutics (acquired by Eli Lilly in 2014) where he was co-founder and Chief Scientific Officer. Prior to Arteaus, Scott was a Founder and Chief Scientific Officer of Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for prostate cancer. Scott has also held positions as Senior Vice President of Research at Dyax, identifying therapeutic antibodies using phage display, and as Chief Scientist at Serono.
Scott received his PhD in Neuroscience from the University of Maryland School of Medicine. He has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 19 issued U.S. patents.
Stefano has led the small molecule drug discovery programs at iTeos since 2012. He was previously at Merck Serono for 10 years directing medicinal chemistry for various target classes and therapeutic areas. Stefano holds a Chemistry degree from Pavia University and a Ph.D. in Organic Chemistry from Southampton University.
He has authored 23 peer-reviewed publications and is an inventor of 20 patent applications.
Jo joined iTeos as Chief Medical Officer in April 2019.
Before joining iTeos, Jo had more than 15 years of experience in Oncology drug development at GSK and Sanofi, most recently as the Head of Global Oncology Development at Sanofi. Here, she was responsible for the entire Oncology portfolio from preclinical development through to post-marketing commitments and life-cycle management, significantly rebuilding the portfolio during her five years in this role. Jo earned her M.D. and trained as a Pediatric Hematologist/Oncologist at Duke University and practiced Pediatric Blood and Marrow Transplantation at Duke University Hospital. She has authored or co-authored 20 peer-reviewed publications.
Yves joined iTeos as Chief Financial Officer in April 2016. He brings more than 25 years of experience in finance and general management. He was previously CFO of Etex Group and Aliaxis, two large international privately-owned industrial groups. From 2009 to 2015, Yves was also CEO of Aliaxis.
Yves holds a Commercial Engineering degree from the Solvay Brussels School of Economics and Management and a Ph.D. in Economics from the London School of Economics.
Greg Sieczkiewicz joined MPM in 2015. Greg serves as Chief IP Counsel at several MPM portfolio companies. Greg has been the architect of IP strategy at over two dozen venture-backed life sciences companies working across the spectrum-in nucleic acid therapeutics, oral biologics, the microbiome, oncology, and protein engineering. He was previously Vice President, IP at Flagship Ventures. Earlier in his career, Greg practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag.
Greg completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School.
Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the United States Patent and Trademark Office. Greg is the former President of the Boston Patent Law Association.